{"name":"GluBio Therapeutics Inc.","slug":"glubio-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOak9zM3hlMXY2RmplTVFEOXprb0ZLbXI1NnpXTzBFWmwtTUU4cVZLRzRpRVFqV1l1VzBwZ1hQQjJYMnJYU0tIU0dpRElseTVxcUlZREhBOTNGR0UyamFaMFduak1POW5vemYyMWhGNWU3V0ltbHprREtlVVhNS3F4TkthZEF3SDY2T2ZBV3U5UFNJWWxBWjBDNUttWlZsb3dxSmwzMWF4cmdmb1hy?oc=5","date":"2026-02-17","type":"deal","source":"BioCentury","summary":"Gilead-Genhouse tie-up among several spanning Pacific: Deals Report - BioCentury","headline":"Gilead-Genhouse tie-up among several spanning Pacific: Deals Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9NbUZuN19MN1E5Z3JQSGRiTVg0Z3JwR0ZpS0NUTkQtSk1EMFMyd3lUOTQ5amVDLVdWTnNzVGtxdWI1dWtkNmxPN3FYRmFVVWE4OS1N?oc=5","date":"2026-02-11","type":"pipeline","source":"FirstWord Pharma","summary":"Biopharma bites: AstraZeneca's former China head formally charged, plus funding for GluBio, Galecto - FirstWord Pharma","headline":"Biopharma bites: AstraZeneca's former China head formally charged, plus funding for GluBio, Galecto","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNc0lZcmVrN3JrOTc5Z3d6dm96ekJ0SThwMmVtTnloeEJmMHh1cUIxNWs3ZDMtSnRyaWE4Uk1OaTdvcHhIT3RPVHNrbHZSUGV5T3drYjFqQzVGRWdEVGVKWEZqTS1kaV96bFowcXF2LWxESXhHd2ZJZjdpQ3ZUSWRqbGpvand4ZVVZczl5QVZRLUhjTGNGUFFnOVp2VnpmZw?oc=5","date":"2026-02-11","type":"trial","source":"endpoints.news","summary":"Exclusive: Sanofi invests in China startup developing molecular glue for sickle cell disease - endpoints.news","headline":"Exclusive: Sanofi invests in China startup developing molecular glue for sickle cell disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNNVF1QWFHMzlsLVg3UEU2NUFqalY0WmpQRGxrdWt6XzduZ1B3aXpOLWlKczQ0OWE1Q2QwbFlOVU9DcktxYUZoQmdzcERXSWI3NVlRNVhqeFM4MkMzV096X3FVR2Y4Rlp5VWlGVkwyd3BPZjhCMGFzLThKSFNqRTQ1eEhaNUhfdG1EQjhNUXhCczJ3anVvaUlIRFYwOUpwdUQtazNxSW1QcG4zUmFnQVJUSlVQT3Q?oc=5","date":"2025-09-01","type":"pipeline","source":"BioSpectrum Asia","summary":"Unlocking the Undruggable with Targeted Protein Degradation - BioSpectrum Asia","headline":"Unlocking the Undruggable with Targeted Protein Degradation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNaGFRSTdGR1QtUGJrOHUxdVVqbVFrTFRzai1sUGVKVXNySkgxNG9rR2Jwa1FPUXNxYkpOeWpWZERHYkZoNnRzSUN0ZUh5TEwxUHhOdGk5SnNrNFhNNTBab0VjcmU1akM3ejlLZkdRbzVoOVA2akk2SWcxcFlpYnVhZXBuVDY?oc=5","date":"2025-05-08","type":"trial","source":"Oncology Pipeline","summary":"C4 takes the Ikaros/Aiolos battle to Bristol | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"C4 takes the Ikaros/Aiolos battle to Bristol | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQQWo3aVRDWFNXdFk4SFN3NkxzLV9WUHBBWkxUMUgyTUdTMXRJd0ZzdmVVeXptcmtVLUtYbnlZa05HWkJmVW1GcmtQTUN3RFhNTHNMX09RUU0tUUJaclhhZ3E4ZWhKb0tDSWRkQ0dmZDZHOXl1ODBNdmgyTXJleXpIOFl6MW9rZw?oc=5","date":"2024-01-24","type":"trial","source":"Oncology Pipeline","summary":"OncoC4 takes its Siglec-10 bet into the clinic | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"OncoC4 takes its Siglec-10 bet into the clinic | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE1pVXBpbnNHNmxBMVBVZjBlT0czcXFqVEVxVkZOVWVYSERvQ0xwQ21vT19CTWRVNm9RVFdiMVNTX2tQbkVuQVR0X1d3TUpVUHJYLU5hZG1lZ3NjelhzZzJLVDhSMTdaaktDa3VHMW8yYjZvekE?oc=5","date":"2023-11-27","type":"trial","source":"Oncology Pipeline","summary":"TROP2 gets more crowded | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"TROP2 gets more crowded | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNbHVVeHBJbnRJZXNZUVVpQWZnVjFTdjBRc05wSEZ6MktOaEpCNFNrZUZGSkZBWXZkQnVhcEZEOXhWbVNLZEdlbmRtRnlkeWxkMHhpWG1VM00xUXlSczhiYnl3ZUd0cDFTNXY1RU1LTlZSWDZWZ2VFN05oaFdPa09lUE10WHppTlVTeVNnakxHOThjZUpPWFJuQ2hQTkZnc3hvZGpRajM4U2VJNkFHb0liZ1BkYw?oc=5","date":"2022-08-11","type":"pipeline","source":"BioWorld News","summary":"Glubio nets $22M in series A+ round for targeted protein degradation drugs - BioWorld News","headline":"Glubio nets $22M in series A+ round for targeted protein degradation drugs","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}